Literature DB >> 24157020

Prognostic value of model for end-stage liver disease scores in patients with fulminant hepatic failure.

H S Lee1, G H Choi, D J Joo, M S Kim, S I Kim, K H Han, S H Ahn, D Y Kim, J Y Park, J S Choi.   

Abstract

BACKGROUND: This study was undertaken to investigate risk factors of mortality in patients with fulminant hepatic failure (FHF).
METHODS: Fifty-three patients with FHF treated from January 2006 to April 2011 were allocated to a spontaneous survival group (group 1), a death without liver transplantation (LT) group (group 2), and an LT group (group 3). To analyze risk factors associated with mortality in FHF, we excluded group 3 patients. Clinical features, Model for End-Stage Liver Disease (MELD) scores, and King's College Hospital criteria at the time of hepatic encephalopathy in group 2 were compared with those of group 1.
RESULTS: The causes of FHF were acute viral infection (n = 29, hepatitis A:B, 28:1), drugs (n = 18; including 4 acetaminophen and 14 herbal medication), autoimmune (n = 4), and miscellaneous (n = 2). Of the 53 patients, 19 were allocated to group 1, 18 to group 2, and 16 to group 3. According to univariate analysis, risk factors for mortality in group 2 were acute renal failure requiring renal replacement therapy and a MELD score ≥30 at the time of hepatic encephalopathy. However, by multivariate analysis, a MELD score ≥30 was the only independent risk factor for mortality in group 2 (P = .042; hazard ratio, 4.500).
CONCLUSIONS: A MELD score ≥30 was found to be the only independent risk factor of mortality in FHF patients without LT. Therefore, the findings of this study suggest that these patients may need emergent LT for survival.
Copyright © 2013. Published by Elsevier Inc.

Entities:  

Mesh:

Year:  2013        PMID: 24157020     DOI: 10.1016/j.transproceed.2013.08.036

Source DB:  PubMed          Journal:  Transplant Proc        ISSN: 0041-1345            Impact factor:   1.066


  5 in total

1.  Letters to the editor.

Authors:  Ronald G Amedee
Journal:  Ochsner J       Date:  2014

Review 2.  Indian National Association for the Study of the Liver Consensus Statement on Acute Liver Failure (Part 1): Epidemiology, Pathogenesis, Presentation and Prognosis.

Authors:  Anil C Anand; Bhaskar Nandi; Subrat K Acharya; Anil Arora; Sethu Babu; Yogesh Batra; Yogesh K Chawla; Abhijit Chowdhury; Ashok Chaoudhuri; Eapen C Eapen; Harshad Devarbhavi; RadhaKrishan Dhiman; Siddhartha Datta Gupta; Ajay Duseja; Dinesh Jothimani; Dharmesh Kapoor; Premashish Kar; Mohamad S Khuroo; Ashish Kumar; Kaushal Madan; Bipadabhanjan Mallick; Rakhi Maiwall; Neelam Mohan; Aabha Nagral; Preetam Nath; Sarat C Panigrahi; Ankush Pawar; Cyriac A Philips; Dibyalochan Prahraj; Pankaj Puri; Amit Rastogi; Vivek A Saraswat; Sanjiv Saigal; Akash Shukla; Shivaram P Singh; Thomas Verghese; Manav Wadhawan
Journal:  J Clin Exp Hepatol       Date:  2020-04-28

3.  Changes in cellular proliferation and plasma products are associated with liver failure.

Authors:  Juliana Gil Melgaço; Frederico Marianetti Soriani; Pedro Henrique Ferreira Sucupira; Leonardo Assaf Pinheiro; Yasmine Rangel Vieira; Jaqueline Mendes de Oliveira; Lia Laura Lewis-Ximenez; Cristina Carvalho Vianna Araújo; Lúcio Filgueiras Pacheco-Moreira; Gustavo Batista Menezes; Oswaldo Gonçalves Cruz; Claudia Lamarca Vitral; Marcelo Alves Pinto
Journal:  World J Hepatol       Date:  2016-11-18

4.  Complement System as a Target for Therapies to Control Liver Regeneration/Damage in Acute Liver Failure Induced by Viral Hepatitis.

Authors:  Juliana Gil Melgaço; Carlos Eduardo Veloso; Lúcio Filgueiras Pacheco-Moreira; Claudia Lamarca Vitral; Marcelo Alves Pinto
Journal:  J Immunol Res       Date:  2018-10-08       Impact factor: 4.818

5.  Creatinine-lactate score predicts mortality in non-acetaminophen-induced acute liver failure in patients listed for liver transplantation.

Authors:  Estela Regina Ramos Figueira; Joel Avancini Rocha-Filho; Cinthia Lanchotte; Lucas Souto Nacif; Luciana Bertocco de Paiva Haddad; Adriana Rochetto Assalin; Yumi Ricucci Shinkado; Agustin Moscoso Vintimilla; Flavio Henrique Ferreira Galvao; Luiz Augusto Carneiro D'Albuquerque
Journal:  BMC Gastroenterol       Date:  2021-06-07       Impact factor: 3.067

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.